---
title: "RGNX.US (RGNX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RGNX.US/news.md"
symbol: "RGNX.US"
name: "RGNX.US"
parent: "https://longbridge.com/en/quote/RGNX.US.md"
datetime: "2026-05-20T12:59:12.157Z"
locales:
  - [en](https://longbridge.com/en/quote/RGNX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RGNX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RGNX.US/news.md)
---

# RGNX.US (RGNX.US) — Related News

### [16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences](https://longbridge.com/en/news/286813324.md)
*2026-05-18T20:05:39.000Z*
> REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in upcoming investor conferences, including the RBC Capital Ma

### [Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price](https://longbridge.com/en/news/286599401.md)
*2026-05-15T17:59:05.000Z*
> Bank of America has lowered its price target for REGENXBIO (NASDAQ:RGNX) from $25.00 to $14.00 while maintaining a 'buy'

### [Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)](https://longbridge.com/en/news/286567070.md)
*2026-05-15T12:38:12.000Z*
> Morgan Stanley analyst Judah Frommer has reaffirmed a Buy rating for RegenXBio (RGNX) with a price target of $16.00. Fro

### [Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint](https://longbridge.com/en/news/286455339.md)
*2026-05-14T18:39:00.000Z*
> Regenxbio's shares fell 36% after reporting a Q1 net loss of $1.72 per diluted share, down from earnings of $0.12 a year

### [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://longbridge.com/en/news/286414953.md)
*2026-05-14T12:05:58.000Z*
> In Thursday's pre-market session, several health care stocks experienced significant movements. Alpha Compute (ALP) surg

### [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
*2026-05-14T16:03:30.000Z*
> REGENXBIO Inc. announced positive results from its Phase 1/2/3 AFFINITY DUCHENNE trial for RGX-202, a gene therapy for D

### [RegenXBio Advances RGX-202 With Positive Phase III Results](https://longbridge.com/en/news/286412399.md)
*2026-05-14T11:58:21.000Z*
> RegenXBio (RGNX) announced positive Phase III results for RGX-202, meeting primary endpoints in the AFFINITY DUCHENNE tr

### [REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News](https://longbridge.com/en/news/286403513.md)
*2026-05-14T03:01:10.000Z*
> REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock New

### [](https://longbridge.com/en/news/286412001.md)
*2026-05-14T11:54:47.000Z*
> REGENXBIO shares are trading lower after the company reported worse-than-expected Q1 financial results.